酪氨酸激酶抑制剂治疗慢性粒细胞白血病儿童患者的生长迟缓和成人身高

IF 12.8 1区 医学 Q1 HEMATOLOGY Leukemia Pub Date : 2024-12-12 DOI:10.1038/s41375-024-02488-0
Haruko Shima, Chikako Tono, Akihiko Tanizawa, Masaki Ito, Akihiro Watanabe, Yuki Yuza, Kazuko Hamamoto, Hideki Muramatsu, Masahiko Okada, Shoji Saito, Hiroaki Goto, Masaru Imamura, Akiko M. Saito, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada
{"title":"酪氨酸激酶抑制剂治疗慢性粒细胞白血病儿童患者的生长迟缓和成人身高","authors":"Haruko Shima, Chikako Tono, Akihiko Tanizawa, Masaki Ito, Akihiro Watanabe, Yuki Yuza, Kazuko Hamamoto, Hideki Muramatsu, Masahiko Okada, Shoji Saito, Hiroaki Goto, Masaru Imamura, Akiko M. Saito, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada","doi":"10.1038/s41375-024-02488-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"39 2","pages":"508-511"},"PeriodicalIF":12.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors\",\"authors\":\"Haruko Shima, Chikako Tono, Akihiko Tanizawa, Masaki Ito, Akihiro Watanabe, Yuki Yuza, Kazuko Hamamoto, Hideki Muramatsu, Masahiko Okada, Shoji Saito, Hiroaki Goto, Masaru Imamura, Akiko M. Saito, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada\",\"doi\":\"10.1038/s41375-024-02488-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18109,\"journal\":{\"name\":\"Leukemia\",\"volume\":\"39 2\",\"pages\":\"508-511\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41375-024-02488-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41375-024-02488-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

虽然酪氨酸激酶抑制剂(TKIs)可以显著改善慢性髓系白血病(CML)的预后,但长期暴露于TKI仍然是一个主要问题,特别是在儿童中。治疗TKIs儿童的一个关键挑战是生长迟缓[1,2,3,4]。最近,据报道,第一代TKI伊马替尼和第二代TKI达沙替尼都能影响费城染色体阳性急性淋巴细胞白血病患者的生长。我们之前报道过伊马替尼治疗CML儿童的生长迟缓,特别是那些在青春期前治疗的儿童。尽管患者在青春期经常经历追赶生长,但这种追赶的程度以及TKI暴露对成人身高的长期影响仍然知之甚少。我们前瞻性地收集了日本儿童白血病和淋巴瘤研究组(JPLSG) CML-08研究中被诊断为慢性期CML的儿童的数据。身高数据每年收集一次,从诊断前两年开始。成人高度定义为高度增长速度为1 cm/年时所测得的最大高度。身高标准偏差评分(SDS)采用年龄和性别调整的日本标准[6]进行调整,成人身高标准偏差评分采用17岁零6个月的数据。青春期定义为男性睾丸≥3ml,女性乳房≥Tanner 2。定义峰高速度为生长突增时的高速度增量,根据生长曲线[7]计算峰高速度下的年龄。生长突增前的TKI暴露时间定义为TKI暴露至峰高速度的持续时间。收集亲代身高数据,预测成虫身高和范围。目标身高(TH)和目标身高的95%置信区间(TR)的计算公式如下(cm):男性,TH =(母亲身高+父亲身高+ 13)/2,TR = TH±9;女性,(母亲的身高+父亲的身高−13)/ 2,TR = TH±8[8]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia
Leukemia 医学-血液学
CiteScore
18.10
自引率
3.50%
发文量
270
审稿时长
3-6 weeks
期刊介绍: Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues
期刊最新文献
Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415–1418 VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1